On this week's episode of the Business of Biotech, Alex Aravanis, M.D., Ph.D., CEO of Moonwalk Biosciences, talks about the opportunity in obesity beyond GLP-1s. He describes Moonwalk’s adipose-targeted siRNA strategy, the genetics-driven logic behind its targets, and what it takes to fund and build a clinical-stage company. Alex also discusses Moonwalk's recent $70 million Series B raise, using AI to prioritize targets and improve siRNA design, and how weight loss without appetite suppression could preserve lean muscle mass and improve tolerability.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Podden och tillhörande omslagsbild på den här sidan tillhör
Ben Comer. Innehållet i podden är skapat av Ben Comer och inte av,
eller tillsammans med, Poddtoppen.
